戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1                                              Intrapleural administration of MPM cells expressing tiss
2                           In conclusion, the intrapleural administration of TGF-beta2 produced excell
3                          We hypothesize that intrapleural administration of TGF-beta2 would (1) produ
4 ages and dendritic cells and showed that, on intrapleural administration, they induce drastic changes
5                   Mechanical ventilation and intrapleural catheter management must be individualized
6 amics of bronchopleural fistula airflow, and intrapleural catheter management were selected.
7  and outcomes with various ventilator modes, intrapleural catheter techniques, endoscopic placement o
8 response was confirmed by depleting LPM with intrapleural clodronate liposomes, which abrogated the a
9                             We conclude that intrapleural delivery of AAV9 can drive expression of Ch
10 deo-assisted thoracoscopic surgery (VATS) or intrapleural enzyme therapy (IET) in pleural infection r
11 MPM cells promotes tumor cell apoptosis, and intrapleural EPCR gene therapy suppresses MPM progressio
12                                              Intrapleural fibrin precedes visceral-parietal pleural a
13 ydrogenase) when predicting the referral for intrapleural fibrinolysis or thoracic surgery (AUC 0.92
14                                              Intrapleural fibrinolysis with urokinase or alteplase fa
15 pective randomized clinical trials comparing intrapleural fibrinolytic therapy (IPFT) with surgical d
16 ed fluid is key to successful treatment, but intrapleural fibrinolytic therapy did not improve outcom
17  guide the decision on whether to administer intrapleural fibrinolytics.
18                                              Intrapleural HO-1 induction inhibited PMC migration afte
19 vel than did the fluid that results from the intrapleural injection of 10 mg/kg doxycycline or 400 mg
20                                              Intrapleural injection of Ad.EPCR into mice with an esta
21 i-inflammatory agents, tube thoracostomy, or intrapleural injection of sclerosing agents.
22             One group of rabbits received an intrapleural injection of talc (400 mg/kg) and an intram
23  induce less inflammation when compared with intrapleural injection of talc.
24                                              Intrapleural injection of TGF-beta(2) induced a dose-dep
25 asis of this study we conclude that a single intrapleural injection of TGF-beta(2) induces pleurodesi
26                                     A single intrapleural injection of TGF-beta(2) may produce a pleu
27                                          The intrapleural injection of TGF-beta(2) resulted in a dose
28                                              Intrapleural injection of TGF-beta2 produced effective p
29                                              Intrapleural injection of the larger doses of TGF-beta(2
30 e present study was to determine whether the intrapleural injection of transforming growth factor bet
31                                       Single intrapleural injections of TGF-beta(2) at doses of 5.00
32 treated with thoracostomy tube placement and intrapleural instillation of either urokinase or altepla
33                          The optimal role of intrapleural L-NDDP therapy currently remains to be dete
34                                              Intrapleural L-NDDP therapy in this patient population i
35 cal MPE samples, suggesting the potential of intrapleural LNP-CDN for clinical MPE immunotherapy.
36                                              Intrapleural loculation can increase morbidity in hemoth
37                    On day 7 a single dose of intrapleural LTA-T (increasing in each patient) was admi
38                         The toxic effects of intrapleural LTA-T seem to be mild and favourable when c
39 The inflammatory and fibrinolysis-associated intrapleural pathway(s) leading to septation formation h
40 rectomy decortication (P/D) and hyperthermic intrapleural povidone-iodine, prophylactic chest wall ra
41  respiratory rate, while minimizing negative intrapleural pressure decreases airflow across the bronc
42 tricular end-systolic pressure) of increased intrapleural pressure in dilated ventricles.
43                     In anesthetized animals, intrapleural pressure sensors were placed thoracoscopica
44 hallenge were also correlated with increased intrapleural pressure, measured via an esophageal tube.
45 t of positive-pressure-mediated increases in intrapleural pressure.
46 d-expiratory pressure, and limiting negative intrapleural pressure.
47 irway pressures of approximately 7 mm Hg and intrapleural pressures of approximately 3 mm Hg in both
48                            A control dose of intrapleural saline was administered after complete drai
49       Methods: The MIST-3 (third Multicenter Intrapleural Sepsis Trial) was a prospective multicenter
50                             In rabbits given intrapleural single-chain urokinase 24 and 48 hours afte
51                                              Intrapleural siRNA delivery has considerable potential a
52 c motor neurons, and PKCtheta knockdown with intrapleural siRNAs abolishes pLTF.
53                                              Intrapleural siRNAs targeting PKCzeta, an atypical PKC i
54 lly invasive method of microinjection to the intrapleural space.
55                                              Intrapleural t-PA-DNase therapy improved fluid drainage
56 single-chain urokinase 24 and 48 hours after intrapleural tetracycline (n = 10 animals), adhesions we
57                                              Intrapleural therapy using interferon gamma, particularl
58 study treatments for 3 days: double placebo, intrapleural tissue plasminogen activator (t-PA) and DNa
59 s data have shown that the combination of an intrapleural tissue plasminogen activator and deoxyribon
60                                              Intrapleural tissue plasminogen activator plus deoxyribo
61 , 55 years; 44 male, 22 female) who received intrapleural tPA between 2000 and 2006 was performed.
62                                              Intrapleural tPA is effective in improving drainage of l
63 ulation does not increase bleeding risk with intrapleural tPA, but therapeutic anticoagulation is ass
64                  To compare chest drain with intrapleural urokinase and primary video-assisted thorac
65 is no difference in clinical outcome between intrapleural urokinase and VATS for the treatment of chi
66 receive either percutaneous chest drain with intrapleural urokinase or primary VATS.